company · 2269-hk

WuXi Biologics

WuXi Biologics printed H1 on 2026-08-25: revenue RMB 11.787B (+18.4%, +23.4% USD/cc), IFRS GM 46.2%, adj. parent NI RMB 3.306B (+38.4%), backlog $25.1B. FY26 revenue raised to +15–18% RMB / +20–23% cc. Separate from WuXi AppTec.

• Tickers 2269.HK
• Also known as 02269 · 02269.HK · 2269 · 2269.HK · WuXi Biologics · 药明生物